GlassScriptPhysician profile
Darrah Pharr Cooper
NPI 1376169904
$10,323.32
in general payments reported to CMS, 2019-2025
20 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,122 · 2022: $1,544 · 2023: $1,776 · 2024: $2,681 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,636 · Education: $21.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,635.56 |
| Education | $21.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,495.30 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,432.14 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,168.54 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Electromed, INC. | $1,010.10 | 2024-2025 | Smartvest |
| Mylan Specialty L.P. | $526.44 | 2021-2024 | Yupelri |
| Genzyme Corporation | $508.03 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $441.47 | 2021-2025 | Dupixent |
| Verona Pharma, INC. | $297.47 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $281.42 | 2025 | Yupelri |
| Insmed, INC. | $268.42 | 2023-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $268.36 | 2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $211.77 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $117.33 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $92.69 | 2021-2024 | Glassia |
| Abbvie INC. | $64.29 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $41.71 | 2021-2024 | Veklury |
| Teva Pharmaceuticals USA, INC. | $29.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.98 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $26.31 | 2021 | |
| Inspire Medical Systems, INC. | $14.61 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrah Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.